Patents by Inventor Qingbei Zeng

Qingbei Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230135068
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: December 14, 2022
    Publication date: May 4, 2023
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20230122807
    Abstract: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I) which possess BTK inhibitory activity and are accordingly useful in therapy and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of medicaments for use in a therapeutic effect in a warm-blooded animal such as man.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 20, 2023
    Inventors: Quan ZHOU, Changmao SHEN, Xiang CHEN, Wengeng LIU, Rumin WANG, Qingbei ZENG, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Patent number: 11629147
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 18, 2023
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Qingbei Zeng, Changhe Qi, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Patent number: 11571420
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: February 7, 2023
    Assignee: DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
    Inventors: Changhe Qi, Honchung Tsui, Qingbei Zeng, Zhenfan Yang, Xiaolin Zhang
  • Patent number: 11447492
    Abstract: Disclosed are quinazoline compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds which are useful in treating diseases associated ErbBs. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: September 20, 2022
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Zhengtao Li, Wei Zhong, Jiabing Wang, Qingbei Zeng, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Publication number: 20220242884
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as DNA-PK inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat DNA-PK related disorder (e.g., cancer).
    Type: Application
    Filed: May 26, 2020
    Publication date: August 4, 2022
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20220220096
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are useful as JAK kinase inhibitors. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), and methods of using such compounds or compositions to treat respiratory conditions (e.g., asthma or COPD).
    Type: Application
    Filed: April 17, 2020
    Publication date: July 14, 2022
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20210251989
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: September 22, 2020
    Publication date: August 19, 2021
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Patent number: 10898481
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: January 26, 2021
    Inventors: Changhe Qi, Honchung Tsui, Qingbei Zeng, Zhenfan Yang, Xiaolin Zhang
  • Publication number: 20210009600
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 14, 2021
    Inventors: Qingbei ZENG, Changhe QI, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20210009587
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Inventors: Zhengtao LI, Wei ZHONG, Jiabing WANG, Qingbei ZENG, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Patent number: 10858365
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: December 8, 2020
    Inventors: Qingbei Zeng, Changhe Qi, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Patent number: 10822334
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: November 3, 2020
    Inventors: Zhengtao Li, Wei Zhong, Jiabing Wang, Qingbei Zeng, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Publication number: 20200330458
    Abstract: The present disclosure novel pyrazine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 22, 2020
    Inventors: Changhe QI, Honchung TSUI, Qingbei ZENG, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20200331918
    Abstract: The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 22, 2020
    Inventors: Qingbei ZENG, Changhe QI, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20200317669
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Zhengtao LI, Wei ZHONG, Jiabing WANG, Qingbei ZENG, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20180016259
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: June 23, 2017
    Publication date: January 18, 2018
    Inventors: David Yunzhi Li, Jiabing Wang, Zhenfan Yang, Qingbei Zeng, Xiaolin Zhang
  • Patent number: 9718806
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: August 1, 2017
    Assignee: AstraZeneca AB
    Inventors: David Yunzhi Li, Jiabing Wang, Zhenfan Yang, Qingbei Zeng, Xiaolin Zhang
  • Publication number: 20160340342
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: May 24, 2016
    Publication date: November 24, 2016
    Applicant: AstraZeneca AB
    Inventors: David Yunzhi LI, Jiabing WANG, Zhenfan YANG, Qingbei ZENG, Xiaolin ZHANG
  • Patent number: 9375432
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof: which possess inhibitory activity against activating mutant forms of EGFR, and are accordingly useful for their anti-cancer activity and in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 28, 2016
    Assignee: AstraZeneca AB
    Inventors: David Yunzhi Li, Jiabing Wang, Zhenfan Yang, Qingbei Zeng, Xiaolin Zhang